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RESEARCH ARTICLE Open Access
Association of mutations in the Plasmodium
falciparum Kelch13 gene (Pf3D7_1343700)
with parasite clearance rates after
artemisinin-based treatments—a WWARN
individual patient data meta-analysis
WWARN K13 Genotype-Phenotype Study Group
Abstract
Background: Plasmodium falciparum infections with slow parasite clearance following artemisinin-based therapies
are widespread in the Greater Mekong Subregion. A molecular marker of the slow clearance phenotype has been
identified: single genetic changes within the propeller region of the Kelch13 protein (pfk13; Pf3D7_1343700). Global
searches have identified almost 200 different non-synonymous mutant pfk13 genotypes. Most mutations occur at
low prevalence and have uncertain functional significance. To characterize the impact of different pfk13 mutations
on parasite clearance, we conducted an individual patient data meta-analysis of the associations between parasite
clearance half-life (PC1/2) and pfk13 genotype based on a large set of individual patient records from Asia and
Africa.
Methods: A systematic literature review following the PRISMA protocol was conducted to identify studies published
between 2000 and 2017 which included frequent parasite counts and pfk13 genotyping. Four databases (Ovid Medline,
PubMed, Ovid Embase, and Web of Science Core Collection) were searched. Eighteen studies (15 from Asia, 2 from
Africa, and one multicenter study with sites on both continents) met inclusion criteria and were shared. Associations
between the log transformed PC1/2 values and pfk13 genotype were assessed using multivariable regression models
with random effects for study site.
Results: Both the pfk13 genotypes and the PC1/2 were available from 3250 (95%) patients (n = 3012 from Asia (93%),
n = 238 from Africa (7%)). Among Asian isolates, all pfk13 propeller region mutant alleles observed in five or more
specific isolates were associated with a 1.5- to 2.7-fold longer geometric mean PC1/2 compared to the PC1/2 of wild
type isolates (all p≤ 0.002). In addition, mutant allele E252Q located in the P. falciparum region of pfk13 was associated
with 1.5-fold (95%CI 1.4–1.6) longer PC1/2. None of the isolates from four countries in Africa showed a significant
difference between the PC1/2 of parasites with or without pfk13 propeller region mutations.
Previously, the association of six pfk13 propeller mutant alleles with delayed parasite clearance had been confirmed.
This analysis demonstrates that 15 additional pfk13 alleles are associated strongly with the slow-clearing phenotype in
Southeast Asia.
Conclusion: Pooled analysis associated 20 pfk13 propeller region mutant alleles with the slow clearance phenotype,
including 15 mutations not confirmed previously.
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Background
Artemisinin-based combination therapies (ACTs) have
been the WHO recommended treatment for uncompli-
cated Plasmodium falciparum malaria since 2006. Stud-
ies conducted in 2006–2007 reported that P. falciparum
parasites in northwest Cambodia had reduced in vivo
susceptibility to artemisinins [1, 2]. This was manifest as
delayed clearance of parasites from the blood of patients
treated with artesunate monotherapy or ACTs [2]. In
2014, parasites selected in vitro for delayed response to
artemisinins were found to have a mutation in the
kelch13 gene (pfk13, P. falciparum 3D7_1343700) [3, 4],
a locus consistent with genome association studies that
had strongly associated a region of chromosome 13 with
slow parasite clearance [5, 6]. Subsequent clinical studies
in western Cambodia showed that delayed parasite clear-
ance in clinical trials was associated with several non-
synonymous mutations in pfk13. In particular, mutations
in the distinctive propeller region of the Kelch 13
protein (codons 441–726) were associated with slow
parasite clearance and subsequently with reduced arte-
misinin susceptibility in in vitro studies assessing suscep-
tibility of the ring-stage parasites [3, 7, 8]. Recently, the
structure of the propeller region was solved and made
public by the Structural Genetics Consortium [9], mak-
ing it possible to link particular genetic changes with
their position in the molecule. A central role of pfk13
propeller mutations in mediating ring-stage resistance
was confirmed by demonstration that parasites engi-
neered to contain the mutations showed ring-stage re-
sistance to artemisinin whereas parasites with the wild
type allele were sensitive [10].
As pfk13 propeller sequences were determined in P. fal-
ciparum from the Greater Mekong Subregion (GMS), other
Asian sites [6, 11–22], and Africa, Latin America, and
Oceania [23–26]; almost 200 different non-synonymous
mutations have been identified (see [27] and supplementary
tables 6 and 7 in [28]).
The parasite clearance half-life (PC1/2), which mea-
sures the slope of the log-linear component of the para-
site clearance curve, has become established as the best
in vivo metric of P. falciparum artemisinin susceptibility
[29–31]. Although sporadic parasite isolates with pfk13
propeller mutations and occasional patients with slow
parasite clearance have been identified in many parts of
the malaria-endemic world, pfk13 mutant parasites iso-
lated from patients with the slow-clearing in vivo pheno-
type have been demonstrated only in a circumscribed
region of Southeast Asia, initially in western Cambodia
and currently extending to parts of Thailand, Vietnam,
Lao PDR, Myanmar, and Yunnan Province, China.
Within this region, there has been clear evidence of se-
lection and spread of successful artemisinin-resistant
parasite lineages [32]. As expected, artemisinin resistance
has led to further selection of ACT partner drug resist-
ance [33–35]. Outside the GMS, extensive molecular ana-
lyses have shown no evidence that parasites carrying pfk13
propeller SNPs are under directional selection by artemisi-
nins [23, 25, 27, 28, 36]. Taken together, available studies
generally support the conclusion that certain pfk13 pro-
peller mutations mediate delayed parasite clearance fol-
lowing treatment with artemisinin derivatives in Southeast
Asia, but that the pfk13 propeller region mutants observed
outside the GMS do not show an association with slow
parasite clearance [37, 38]. Exceptions include recent mo-
lecular reports of independent emergence of parasites that
carry pfk13 propeller mutant alleles observed previously in
the GMS in Guyana (C580Y) [39] and Rwanda (P574L
and A675V) [40]. Accurate measurement of the parasite
clearance phenotype requires frequent timed blood sam-
pling [41]. This is often impractical and means that many
surveys only collect information on the pfk13 genotypes in
a study area. It is therefore critical to utilize optimally
those studies that do include both genotype and in vivo
phenotype. The WHO has provided guidelines for associ-
ating P. falciparum parasite mutations with slow parasite
clearance in vivo [42]. Currently, 6 pfk13 propeller region
mutant alleles have been validated in this way, 8 additional
alleles have been described as “associated” with the pheno-
type, and 18 other alleles have been isolated in such low
numbers that their phenotype could not be evaluated. It is
also clear that some non-synonymous mutations in the
pfk13 propeller region (notably A578S) are not associated
with artemisinin resistance. The low prevalence of pfk13
propeller alleles outside the Greater Mekong Subregion
has limited our ability to confirm the roles of additional
genotypes in conferring the delayed clearance phenotype.
We have used meta-analysis of individual patient data
from published and unpublished studies to compare
standardized parasite clearance half-life estimates and
pfk13 propeller region genotypes. This analysis capital-
ized on the power of the large data set to allow assess-
ment of the importance of a broader range of propeller
region alleles in mediating slow parasite clearance in
vivo.
Methods
Data acquisition
A systematic literature review following the PRISMA
protocol [43] was conducted to identify studies pub-
lished between 2000 and 2017 which included frequent
parasite measurements and pfk13 genotyping (last run
on 31 January 2018). Four databases (Ovid Medline,
PubMed, Ovid Embase, and Web of Science Core Col-
lection) were searched. The search terms and conditions
are available in Additional file 1.
At the abstract screening stage, we excluded studies that
did not include treatment with artemisinin derivatives,
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pfk13 genotyping or parasite measurements as well as re-
view and correspondence articles. At full-text screening,
we excluded additional studies that measured parasites
less frequently than twice a day. Data were actively re-
quested only from studies that reported parasites that car-
ried pfk13 non-synonymous mutations. However, we
received two studies that found no parasites that carried
these pfk13 mutations and these were analyzed as part of
the wild type data set.
Studies that identified non-synonymous mutations in
pfk13 were eligible for inclusion in this analysis if individ-
ual patient files also met the following criteria: (a) patients
were treated with either an ACT or an artemisinin mono-
therapy; (b) parasitemia was measured in the first days of
treatment at least every 12 h, until a negative count or at
least until day 3, allowing the standardized calculation of
the PC1/2 [29, 30]; (c) the dosing protocol was available;
and (d) the weight of each individual patient was recorded.
The published papers and data sources are listed in detail
in Additional file 2: Table S1 [2, 11, 15, 16, 19, 44–51].
Individual study protocols were available for all trials
included, either from the publication or as a metafile
submitted with the primary data. Individual patient data
from eligible studies were shared, collated, and standard-
ized under the protocols of the WWARN data platform
using previously described methodology [52]. Study re-
ports generated from the formatted datasets were sent
back to investigators for validation or clarification.
Methodologies used in studies regarding parasitemia
sampling and molecular analyses are presented in Add-
itional file 2: Table S1.
Statistical analysis
The statistical analysis plan [53] was developed before
analysis. All non-synonymous mutations in the pfk13
gene identified in the studies were included in the ana-
lysis. Isolates without reported mutations were assumed
to be wild type in assessing relationships between para-
site genotype and PC1/2. Isolates with a mixed genotype
at any nucleotide within the pfk13 coding region (wild
type/mutation or two non-synonymous mutations) were
excluded from the analysis.
The PC1/2 is defined as the time in hours needed for
the parasite density to decline by 50% during the
log-linear phase of parasite clearance. PC1/2 was calcu-
lated using the WWARN parasite clearance estimator
tool [41]. The goodness of fit of parasite clearance
models was evaluated for each individual patient
parasitemia-time profile used to estimate the PC1/2.
Profiles that satisfied the following criteria (i.e., pro-
vided biologically or statistically plausible results) were
included in the analysis: (a) standard deviations of resid-
uals < 2, (b) number of data points used to fit the linear
part of the curve > 2, (c) duration of lag phase < 12 h,
(d) pseudo R2 statistics ≥ 0.8. Additionally, patients who
withdrew or had a record of inadequate dosing were ex-
cluded. The log transformed half-life metric was mod-
eled for all pfk13 mutant alleles in all studies with
information from individual patients on age, initial para-
sitemia, ACT treatment, and artesunate dose as covari-
ates. The method by which the dose was calculated is
documented in the statistical analysis plan. Random ef-
fects for study site were used to account for heterogen-
eity between studies. Residuals were examined for
normality and for systematic deviations from the model.
The differences in PC1/2 between infections with P.
falciparum parasites bearing a specific pfk13 propeller
mutant allele and those with wild type parasites were
assessed by the Wald test. The fold change in geometric
mean of PC1/2 of infections with pfk13 mutant parasites
compared to wild type isolates from the same sites;
xPC1/2 was calculated as an exponent of the difference
of the corresponding regression coefficients.
In order to determine a PC1/2 threshold value that de-
fined slow parasite clearance, we divided Asian data into
two populations: rapid clearing and slow clearing. The
slow-clearing population was defined as all isolates with
mutations associated with a significant increase in PC1/2
values in this analysis, while the fast-clearing population
included all other isolates. The PC1/2 value that corre-
sponds to the 95th percentile of the fast-clearing popula-
tion (i.e., a value x such that the probability that PC1/2 >
x is less than 0.05) was selected as the cutoff for infec-
tions with “slow clearing” parasites. Risk of bias in indi-
vidual studies was assessed based on frequency of
parasite counting, molecular methodology, and number
of patients excluded because of missing data or unsatis-
factory fit of the model for PC1/2 estimation (for details,
see Additional file 1). Data from studies/sites that re-
ported results very different from all of the others in the
same region were included in the analysis, and a sensi-
tivity analysis was conducted after excluding Tra Lang,
Vietnam (study site ID 23; study ID 8), and Pyin Oo
Lwin, Myanmar (study site ID 15; study ID 13).
Results
Literature search
The literature search identified 146 articles, with 9 satis-
fying our inclusion criteria and describing data from 14
studies (Additional file 1). Seven additional studies were
contributed in response to the proposal for this study
group on the WWARN website. Consequently, we re-
quested individual patient data from 21 studies and re-
ceived data from 18 studies.
Description of the study sites
There were 16 studies from Asian sites that reported both
PC1/2 estimates and pfk13 propeller region genotypes from
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Myanmar, Thailand, Cambodia, Lao Peoples Democratic
Republic (PDR), Vietnam, Bangladesh, and Yunnan prov-
ince of China bordering Myanmar. Among these 3179 pa-
tients, 3012 had sufficient data for PC1/2 estimation and
2631 met the inclusion criteria for evaluation of the asso-
ciation of the pfk13 genotype and the parasite clearance
phenotype. Of the Asian isolates, nearly half (43%; 1142/
2631) were from four study sites of the Shoklo Malaria Re-
search Unit (SMRU) along the Western Thailand/Eastern
Myanmar Border; these isolates are identified as a group
called Thai Western Border.
There were 238 isolates with genotype and phenotype
information contributed from five sites in Africa; one
site in Nigeria (n = 31), the Democratic Republic of
Congo—DRC (n = 119), and Tanzania (n = 39); and two
sites in Madagascar (n = 49). A total of 204 patients’ data
met the inclusion criteria for evaluation of the associ-
ation of the pfk13 genotype and the parasite clearance
phenotype (Table 1, Figs. 1 and 2).
Figure 1 depicts the locations of the study sites. Add-
itional file 3: Figure S2 summarizes the numbers of indi-
vidual data sets that met all criteria for inclusion.
Patient characteristics and the numbers of patients
treated with artesunate or artemisinin combination ther-
apies are summarized in Table 2. The median age of pa-
tients in Asia was 21 years, and 77% were 12 years of
age or older; African patients had a median age of
4.7 years, and only 6% were older than 11 years.
Molecular analyses of the pfk13 alleles
Samples were collected between 2001 and 2014. Among
the 45 individual study sites, 33 included data from the
entire pfk13 gene (codons 1–726); 12 studies reported
sequence of only the propeller region codons (441–726).
A total of 202 and 1254 isolates with molecular informa-
tion on mutants in codons 1–440 (P. falciparum-specific
region) and codons 441–726 (the propeller region) were
recorded respectively. The pfk13 genotype of parasites
from 3424 patients was determined; mutant alleles were
identified in 1455 samples. The prevalence of mutant co-
dons observed in each study is summarized in Table 1.
Plasmodium-specific region (codons 1–440)
Data were available for the whole pfk13 molecule in two
African study sites: Kinshasa, DRC (study ID 13; site ID
24), and Ilorin, Nigeria (study ID 13; site ID 36). Ilorin
had the higher prevalence of isolates with mutant co-
dons in the P. falciparum domain (14/36, 39%), com-
pared with Kinshasa (33/117, 28%). In 76% (37/49) of
these isolates, the mutations were at codon 189; 35 car-
ried the K189T mutation, 12 carried a synonymous
K189K, and 2 carried a K189N codon (Additional file 2:
Table S2A).
Complete pfk13 DNA sequence was determined in 18
Asian study sites, including all of the studies from the
Thai Western Border. Mutant codons in the 5′ region of
the gene were rare in most Asian-derived samples. The
K189T mutant codon was observed in samples from
Bangladesh (study 7; site 1: n = 1/21, 5%), (study 16; site
2: n = 4/55, 7%) and two sites in Myanmar ((study 16;
site 16: n = 3/74, 4%), study 12; site 17: n = 1/71, (1.4%))
(Additional file 2: Table S2A).
Many of the parasites from the Thai Western Border
(site 20) shared an allele with a codon change at position
252 from glutamic acid to glutamine (E252Q). Parasites
with this allele were observed in study 1 (n = 1/7, 14%),
study 4 (n = 68/950, 7%), and study 16 (n = 14/116, 12%).
Parasites with this genotype were also observed in Shwe
Kyin in 2011–2013 (study 16, site 16), where they com-
prised 10/74 (14%) of the isolates tested (Additional file 2:
Table S2A), and this allele has been observed near the
Myanmar-China border, as well [14]. In the relatively
conserved stem domain (350–440), mutants were ob-
served only transiently in parasites from Shwe Kyin and
the Thai Western Border.
pfk13 propeller region (codons 441–726)
The sequence of the pfk13 propeller region was deter-
mined in all 45 data sets (Table 1, Additional file 2:
Table S2B). In the African isolates, the only mutant co-
dons identified in the propeller region were in 3/117 iso-
lates from Kinshasa, each with a single mutation
(codons S522C, A578S, or Q613L) and in 4/44 isolates
from Brickaville, Madagascar, all with mutant codon
A578S which is relatively common in Africa and has
been reported in Thailand and Bangladesh [27]. The
Asian data set was dominated by large numbers of pa-
tients from two regions, the Thai Western Border (n =
1291/3087 (42%)) and northwestern Cambodia (n = 847/
3087 (27%)), with smaller numbers from Vietnam,
Myanmar, the Myanmar-China Border, Bangladesh, and
Lao PDR. The detailed data are summarized in
Additional file 2: Table S2B. As has been published, the
Thai Western Border, Thai, Cambodian, Laotian, and
Vietnamese data sets contained numerous isolates with
the pfk13 C580Y allele [11–14, 18, 19, 21, 22, 28, 32, 34,
50, 54, 55]. In contrast, isolates with the Y493H and
R539T mutant codons were common among Cambodian
isolates, but uncommon in samples from Thailand with
the exception of those from Srisaket, a province that
borders Cambodia.
The F446I mutant predominated in data sets from
Myanmar and the China/Myanmar border (n = 83/141,
(59%) [14, 16, 27, 51]. The mutant codons in the propel-
ler region identified among the African isolates, S522C,
S613E, and the very common A578S “African” allele,
were absent from the Asian data set.
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Table 1 Summary of genotyping results by study site. Samples with mixed genotyping are excluded. Details of mutations are listed
in Additional file 2: Table S2A (codons 1–440) and S2B (codons 441–726), and mixed genotypes are listed in Additional file 2: Table
S3. Results are sorted by continent, country, site, and year of study
Study ID Country Site ID Site Year Total N
isolates
Non-synonymous changes between
Codon 1–440 Codon 441–726
N N % [95% CI]
Asia
7 Bangladesh 1 Bandarban 2004–2005 21 2 0 0 [0–15]
16 Bangladesh 2 Ramu 2012 55 4 0 0 [0–7]
9 Cambodia 3 Anlong Veng 2012–2014 107 ND 103 96 [91–99]
2 Cambodia 4 Tasanh 2008–2009 46 ND 38 83 [69–91]
6 Cambodia 5 Pailin 2008–2009 36 ND 34 94 [82–98]
16 Cambodia 5 Pailin 2011–2012 87 0 80 92 [84–96]
10 Cambodia 6 Preah Vihear 2012–2013 65 ND 22 34 [24–46]
11 Cambodia 6 Preah Vihear 2011–2012 110 0 22 20 [14–28]
10 Cambodia 7 Pursat 2012–2013 107 ND 82 77 [68–84]
16 Cambodia 7 Pursat 2011–2012 104 0 77 74 [65–82]
10 Cambodia 8 Ratanakiri 2012–2013 66 ND 7 11 [5–20]
16 Cambodia 8 Ratanakiri 2011–2012 119 0 4 3 [1–8]
11 China 9 Tengchong 2012 12 ND 10 83 [55–95]
11 China 10 Yingjiang 2009–2012 110 ND 61 55 [46–64]
12 LPDR 11 Attapeu 2013–2014 18 0 4 22 [9–45]
14 LPDR 11 Attapeu 2011–2012 118 0 2 2 [0–6]
3 LPDR 12 Savannakhet 2010 33 0 0 0 [0–10]
15 Myanmar 13 Hpa Pun 2013 32 1 14 44 [28–61]
12 Myanmar 14 Myitkyina 2013–2014 43 0 21 49 [35–63]
13 Myanmar 15 Pyin Oo Lwin 2012–2014 31 0 15 48 [32–65]
16 Myanmar 16 Shwe Kyin 2011–2013 74 17 20 27 [18–38]
12 Myanmar 17 Thabeikkyin 2013–2014 71 1 12 17 [10–27]
16 Thailand 18 Ranong 2011–2012 19 0 13 68 [46–85]
16 Thailand 19 Srisaket 2011–2013 34 0 30 88 [73–95]
4 Thailand 20 TW border 2001 9 0 0 0 [0–30]
4 Thailand 20 TW border 2002 58 0 0 0 [0–6]
4 Thailand 20 TW border 2003 33 3 0 0 [0–10]
4 Thailand 20 TW border 2004–2006 28 0 0 0 [0–12]
4 Thailand 20 TW border 2007 26 2 1 4 [1–19]
4 Thailand 20 TW border 2008 341 30 57 17 [13–21]
1 Thailand 20 TW border 2008 5 1 1 20 [4–62]
4 Thailand 20 TW border 2009 227 38 47 21 [16–26]
4 Thailand 20 TW border 2010 138 20 46 33 [26–42]
4 Thailand 20 TW border 2011 113 17 66 58 [49–67]
16 Thailand 20 TW border 2011–2012 94 5 61 65 [55–74]
4 Thailand 20 TW border 2012 116 14 80 69 [60–77]
4 Thailand 20 TW border 2013 80 1 67 84 [74–90]
4 Thailand 20 TW border 2014 23 0 21 91 [73–98]
16 Viet Nam 21 Binh Phuoc 2011–2012 103 0 28 27 [20–36]
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Association of pfk13 mutations and parasite clearance
half-life
Among 3329 patients with pfk13 genotyping results that
reported only a single mutation in the propeller region,
PC1/2 values were estimated in 3156 (95%) patients. In 165
patients, PC1/2could not be estimated because the data
were too sparse, the initial parasitemia was too low (< 100
parasites per microliter) (n = 3) or the last recorded para-
sitemia was too high (> 10,000 parasites per microliter) (n
= 6). Overall, 90% (2834 of 3156) of PC1/2 estimates were
classified as suitable for analysis (using criteria specified
prospectively in the methods, and Fig. 2).
Defining the groups of slow- and fast-clearing parasites
Two populations of parasites were identified among the
Asian parasites: fast-clearing (loge PC1/2 mean, 1.0 SD,
0.41) and slow-clearing including all isolates with muta-
tions listed in Tables 3 and 7 (logePC1/2 mean 1.9; SD
0.19). These groups had corresponding half-life geomet-
ric means of 2.7 h and 6.7 h, respectively. A PC1/2 equal
to 5.5 h corresponds to the 95th percentile of the
fast-clearing parasite population, and the probability of
observing PC1/2 > 5.5 h in a single isolate coming from a
sensitive population is equal to 0.043. On this basis, a
median value of PC1/2 > 5.5 h was used to define para-
sites associated with slow clearance.
African isolates
Summary statistics of PC1/2 estimates and their associ-
ation with pfk13 mutations are presented in Table 5 and
Additional file 3: Figure S3A for wild type (median PC1/2
Table 1 Summary of genotyping results by study site. Samples with mixed genotyping are excluded. Details of mutations are listed
in Additional file 2: Table S2A (codons 1–440) and S2B (codons 441–726), and mixed genotypes are listed in Additional file 2: Table
S3. Results are sorted by continent, country, site, and year of study (Continued)
Study ID Country Site ID Site Year Total N
isolates
Non-synonymous changes between
Codon 1–440 Codon 441–726
N N % [95% CI]
5 Viet Nam 22 Phuoc Long 2010–2011 92 0 34 37 [28–47]
8 Viet Nam 23 Tra Lang 2012 83 ND 67 81 [71–88]
Africa
16 DRC 24 Kinshasa 2013 117 32 3 3 [1–7]
18 Madagascar 25 Ankazobe 2014 5 ND 0 0 [0–43]
18 Madagascar 26 Brickaville 2014 44 ND 4 9 [4–21]
16 Nigeria 27 Ilorin 2011–2012 36 14 0 0 [0–10]
17 Tanzania 28 Fukayosi 2012 41 ND 0 0 [0–10]
DRC Democratic Republic of Congo, LPDR Lao People’s Democratic Republic, TW border Thai Western border, ND not done
Fig. 1 Study site locations. The numbers in the pins correspond to the study sites listed in Table 1
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2.2 h, range 0.7–6.3) and mutant K189T (median PC1/2
2.1 h, range 0.8–7.1). Additional file 3: Figure S3B shows
individual PC1/2 values for all other mutations observed
in African isolates.
The PC1/2 values in wild type isolates from the five African
sites were all well below the cutoff of 5.5 h, but varied sig-
nificantly from one another (p = 0.004, Additional file 3: Fig-
ure S1). Compared to wild type isolates in Kinshasa, DRC,
an area of high perennial transmission, the PC1/2 in wild
type isolates was 1.36 times longer (95%CI 1.08–1.70; p=
0.008) in Brickaville, Madagascar, 1.46 times longer (95%CI
1.18–1.8; p= 0.001) in Ilorin, Nigeria; and not significantly
different in Fukayosi, Tanzania (p= 0.117), or Ankazobe,
Madagascar (p= 0.199) (Additional file 3: Figure S1).
Most pfk13 mutations were rare in the African data
sets, being observed in fewer than four isolates (Figure 3).
Among a total of seven isolates with a propeller muta-
tion (S522C, A578S, or Q613L), four met the inclusion
criteria for evaluation of the association of the pfk13
genotype and the parasite clearance phenotype. All of
Fig. 2 Study profile. Definitions for specific exclusions are listed at the right of the figure detailing the number of isolates included in each analysis.
Unsatisfactory fit was defined as pseudo-R2 statistics < 0.8. Insufficient parasite data includes patients with too few observations to fit the model and
patients with only daily counts
Table 2 Baseline characteristics and treatment administered. Only patients with genotyping and PC1/2 results are presented
Asia Africa
N Median (range) or N (%) N N (%) or median (range)
Age (years) 2630 21 [0.1–70] 204 4.7 [0.7–29]
< 1 year 8 [0] 11 [5]
1–4 years 185 [7] 98 [48]
5–11 years 407 [15] 82 [40]
12+ years 2030 [77] 13 [6]
Parasitemia (microliter) 2631 97,214 [455–2,409,008] 204 53,507 [2240 - 605,329]
Temperature (C) 1658 38.2 [34.1–41.5] 204 37.6 [34.7–40.8]
Hemoglobin (g/dL) 770 13.1 [2.1–19.3] 26 10.8 [6.3–14.2]
Hematocrit (%) 1542 40 [12–55] 140 31 [21–44]
Artemisinin derivative: total 3 days dose (mg/kg)
AL 0 80 9.3 [5.2–16.0]
AS 433 8.3 [1.0–49.7] 0
AS + ACT1 1638 8.3 [0.5–28.9] 83 11.8 [4.7–15]
ASAQ 0 41 13.0 [8.6–16.7]
ASMQ 81 8.0 [3.8–16.1] 0
DHAPIP 430 6.7 [3.0–17.8] 0
1Artesunate was given in the first 3 days alone, followed by ACT
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the seven isolates had PC1/2 < 2.8 h and exhibited no in-
crease in PC1/2 compared to infections with wild type
parasites. In fact, the geometric mean of PC1/2 was lower
in isolates with propeller mutations compared to wild
type isolates at the same study sites (p = 0.491 and p =
0.096 when seven or four isolates were included). In this
dataset, only the A578S allele of the propeller mutations
observed in Africa was also observed in Asia, but in only
three isolates. The median half-life for mutations any-
where in the pfk13 gene ranged from 1.7 to 2.7 h (Add-
itional file 3: Figure S3A and S3B).
Codon K189T/N was present in 33 isolates (31 were
K189T and 2 were K189N), sufficient numbers to assess the
overall parasite clearance; these infections had a median
PC1/2 of 2.1 h (range 0.8–7.1) similar to that of infections
with wild type parasites; 2.2 h (range 0.7–6.3) (Fig. 3a).
Asian isolates
Among Asian isolates, 1440 were wild type and 1190
carried a single pfk13 mutation. The prevalence of iso-
lates with a PC1/2 > 5.5 h and the median PC1/2 both var-
ied depending on the pfk13 mutation (Table 5, Fig. 4).
The 32 studies with infections caused by P. falciparum
isolates that carried a non-synonymous change within co-
dons 1–440 were analyzed, and all 45 studies with sequence
information on the propeller regions were analyzed.
Variance in PC1/2 between genotypes was significantly
larger than within genotypes (F40, 2554 = 48.43, p < 0.001,
Table 3 Comparison of PC1/2 between patients with WT and a pfk13 NS-mutation in Asia. Metric is the fold increase of PC1/2 in
mutants vs. wild type. Only mutations with n ≥ 5 are shown. With only two exceptions (K189T and K438N), all patients that carried
parasites with the indicated pfk13 mutant codon showed a PC1/2 significantly different from those that carried WT parasites
Comparison of PC1/2
N with N with Univariable Multivariable1
Codon mutation WT xPC1/2 95%CI p value xPC1/2 95% CI p value
K189T 8 148 1.1 0.8–1.4 0.729 1.1 0.8–1.4 0.644
E252Q 114 589 1.5 1.4–1.6 < 0.001 1.5 1.4–1.6 < 0.001
K438N 10 386 0.9 0.7–1.1 0.251 0.9 0.7–1.1 0.237
P441L 53 565 2.1 1.9–2.3 < 0.001 2.2 2.0–2.4 < 0.001
F446I 79 303 1.6 1.4–1.7 < 0.001 1.5 1.4–1.7 < 0.001
G449A 6 41 1.9 1.4–2.6 < 0.001 1.9 1.3–2.7 < 0.001
N458Y 34 520 2.5 2.2–2.8 < 0.001 2.5 2.2–2.8 < 0.001
M476I 8 481 2 1.6–2.5 < 0.001 2.0 1.5–2.5 < 0.001
A481V 5 410 1.8 1.3–2.4 < 0.001 1.6 1.2–2.2 0.002
Y493H 33 313 2.6 2.2–3.0 < 0.001 2.7 2.3–3.1 < 0.001
R515K 5 352 1.9 1.4–2.6 < 0.001 2.0 1.5–2.7 < 0.001
P527H/L* 23 422 1.7 1.5-2.0 < 0.001 1.7 1.5–2.0 < 0.001
N537I 8 231 1.7 1.3–2.2 < 0.001 1.8 1.4–2.3 < 0.001
G538V 24 558 1.8 1.6–2.1 < 0.001 1.9 1.6–2.2 < 0.001
R539T 76 369 2.1 1.9–2.4 < 0.001 2.1 1.9–2.4 < 0.001
I543T 92 156 1.9 1.7–2.3 < 0.001 2.1 1.8–2.4 < 0.001
I543T** 27 140 2.8 2.3–3.4 < 0.001 2.8 2.3–3.5 < 0.001
P553L 16 529 2.2 1.8–2.6 < 0.001 2.2 1.8–2.8 < 0.001
R561H 36 310 2.2 1.9–2.5 < 0.001 2.2 1.9–2.6 < 0.001
V568G 5 127 2.7 1.8–4.1 < 0.001 2.7 1.8–4.1 < 0.001
P574L 48 739 1.8 1.6–2.0 < 0.001 2.0 1.7–2.2 < 0.001
P574L*** 35 723 1.8 1.6–2.1 < 0.001 1.8 1.6–2.1 < 0.001
C580Y 450 997 2.2 2.1–2.4 < 0.001 2.3 2.1–2.4 < 0.001
P667T**** 5 50 2.2 1.6–2.9 < 0.001 2.1 1.6–2.9 < 0.001
A675V 49 501 2.2 1.9–2.4 < 0.001 2.2 2.0–2.4 < 0.001
1Adjusted for total artemisinin derivative dose in the first 3 days, partner drug, initial parasitemia and patient age
*20 P527H, one P527L, analyzed together, two P527H not analyzed since clearance data did not meet criteria
**With study ID 8, study site ID 23 (Tra Lang) removed
***With study ID 13, study site ID 15 (Pyin Oo Lwin) removed
****5 P667T, one P667T not analyzed since clearance data did not meet criteria
WWARN K13 Genotype-Phenotype Study Group BMC Medicine            (2019) 17:1 Page 8 of 20
Fig. 3 Distribution of parasite clearance half-life by individual wild type or pfk13 mutant codons in isolates from Africa. Left panel (a) shows violin
plots for wild type or mutant codons with five or more isolates. The number of individual isolates tested is at the right of each violin plot. The
right panel (b) shows dot plots for mutant codons with < 5 isolates. The red line shows a half-life of 5.5 h. The median is shown as a green circle,
the red bar corresponds to the interquartile range, and the curve represents kernel estimate of the density function
Fig. 4 Distribution of parasite clearance half-life by pfk13 mutant codons in isolates from Asia. Left panel (a) shows violin plots for mutant codons
with five or more isolates. The number of individual isolates tested is at the right of each violin plot. The right panel (b) shows dot plots for
mutant codons with < 5 isolates. The red line shows a half-life of 5.5 h. The median is shown as a green circle, the red bar corresponds to the
interquartile range, and the curve represents kernel estimate of the density function. * 22 P527H and 1 P527L with PC1/2 = 5.8h; ** 6 P667T and
1 P667R without valid PC1/2 measurement, so not considered
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after adjusting for study site). All infections with pfk13
mutants in the propeller region that were reported in
five or more isolates were associated significantly with a
geometric mean PC1/2 greater than that in infections
with wild type parasites (p < 0.001 for all but codon
A481V, in which p = 0.002). The fold increase in geomet-
ric mean of PC1/2 (xPC1/2), compared to the PC1/2 of
wild type parasites at the same sites, ranged from 1.5 to
2.7 (Table 3). Parasites with mutations F446I, G449A,
A481V, P527L, N537I, G538V, and P574L had a fold in-
crease between 1.5 and 1.9, and all others were between
2.0 and 2.7. Neither isolates with the K189T mutation
nor K438N showed any increase in PC1/2 compared with
wild type parasites (p = 0.644 and 0.237, respectively).
However, isolates with the E252Q mutation (which is
also outside the propeller region) from both the Western
Thai Border and Shwe Kyin, Myanmar, had a significant
increase in PC1/2, 1.5-fold (xPC1/2 = 1.5; 95%CI 1.4–1.6)
compared with wild type parasites (p < 0.001).
For infections caused by parasites that carried only
wild type pfk13, the distribution of PC1/2 values varied
significantly between locations (Additional file 3: Figure
S2, p < 0.001); one site in Myanmar, Pyin Oo Lwin, and
one in Vietnam, Tra Lang, had a median PC1/2 of wild
type isolates that was above the cutoff of 5.5 h and above
the PC1/2 observed for wild types in other sites (p <
0.001). At both sites, no significant differences were ob-
served in PC1/2 between K13 wild type and K13 mutant
isolates. The corresponding factor for change in PC1/2 in
mutant isolates was estimated as 0.91 (0.74–1.12) p =
0.367 for Tra Lang, Vietnam, and 0.90 (0.73–1.10) p =
0.274 for Myanmar, Pyin Oo Lwin. Four mutant pfk13
alleles were associated with significant differences in
PC1/2 between different study sites: E252Q (p < 0.001),
F446I (p = 0.005), M476I (p = 0.014), Y493H (p =
0.029) and C580Y (p < 0.001) (Table 4, Additional file 3:
Figures S3-S7).
Between 2009 and 2014, the prevalence of the C580Y
allele in parasite populations on the Thailand western
border increased [18]. This change was accompanied by
a progressive increase in the median PC1/2 of infections
with pfk13 C580Y mutants, from a median of 5.4 h in
2009 to 7.2 h in 2014 (Additional file 3: Figure S8). A
linear trend of increase in the geometric mean of PC1/2
by 5.0% (95%CI 2.3–7.9) each year (xPC1/2 = 1.05; 95%
CI 1.02–1.08) was observed (p < 0.001), and the linear
trend was not affected by differences in patient treat-
ment or artemisinin derivative dose.
Influence of patient characteristics and antimalarial
treatment drugs on PC1/2 in Asian isolates
Differences between PC1/2 values for parasites with the
same pfpk13 genotype were not significant when ad-
justed for patients’ initial parasitemia, artesunate dose,
age, and study site. However, within the data set, pa-
tients whose parasite clearance was assessed had been
treated with a range of artemisinin derivatives and doses
and ACT partner drugs (Table 2). Groups with sufficient
numbers of isolates (WT, F446I, Y493H, R539T, I543T,
P553L, P574L, C580Y) were compared to assess the ef-
fects of the drugs administered on the half-life of para-
site clearance. No differences in parasite clearance
half-life among these different drug treatments were ob-
served with one exception: the comparison between
treatment with artesunate alone and artesunate/meflo-
quine in isolates with a WT genotype. Infections in pa-
tients treated initially with artesunate + mefloquine had
a geometric mean PC1/2 0.8 times (95%CI 0.7–0.9, p <
0.001) shorter than those treated with artesunate alone.
Correspondence of PC1/2 > 5.5 h and day 3 parasitemia
Collecting frequent parasite counts in patients several
times per day is not always feasible, and so recording the
proportion of patients that remain parasitemic at day 3
after treatment has been proposed as a simple more
practical warning signal for the possible slow clearance
phenotype [29, 56]. To assess the correspondence
Table 4 Comparison of PC1/2 for pfk13 NS mutations between
study sites in Asia. Only mutations with isolates available from
at least five patients from at least two sites are shown
Mutant
codon
N
sites
N
patients
p value for comparison by site
Univariable Multivariable1
K189T 3 8 0.324 0.278
E252Q 2 114 < 0.001 < 0.001
K438N 2 10 0.007 0.322
P441L 3 53 0.991 0.908
F446I 7 79 0.002 0.005
G449A 3 6 0.013 No data2
N458Y 2 34 0.583 0.249
M476I 3 8 < 0.001 0.014
A481V 2 5 0.664 No data2
Y493H 7 33 0.050 0.029
R515K 2 8 0.525 No data2
G538V 2 24 0.599 No data2
R539T 9 76 0.623 0.766
I543T 4 77 0.084 0.821
P553L 4 16 0.654 0.228
R561H 4 36 0.219 0.183
V568G 2 5 0.563 No data2
P574L 7 38 0.001 0.003
C580Y 13 450 < 0.001 < 0.001
1Adjusted for total artemisinin derivative dose in the first 3 days, partner drug,
initial parasitemia and patient age
2Could not fit multivariable model due to small number of observations,
overall or within sites
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Table 5 Summary of PC1/2 by mutant codon and region showing proportion of isolates from a study site with PC1/2 > 5.5 h and
proportion of Day 3 positive isolates. Mutant codons represented by fewer than 5 isolates are indicated in bold
N Patients with
PC1/2 > 5.5 h (%)
PC1/2 Percentiles (hours) Patients positive
on day 3 (%)Median 25 75 5 95 Min Max
Asia
WT 1440 5 2.7 2.1 3.4 1.4 5.3 0.7 12.4 9
G112E 1 0 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0
K189 T 8 0 2.8 2.1 4.0 1.3 4.3 1.3 4.3 0
I205T 1 100 6.8 6.8 6.8 6.8 6.8 6.8 6.8 100
R223K 1 0 3.0 3.0 3.0 3.0 3.0 3.0 3.0 0
R239Q 3 0 4.6 3.7 5.2 3.7 5.2 3.7 5.2 67
E252Q 114 11 4.4 3.8 5.0 2.8 6.6 2.0 7.4 46
D281V 3 0 3.7 2.9 5.4 2.9 5.4 2.9 5.4 33
K438 N 10 0 2.4 2.2 2.9 1.4 3.7 1.4 3.7 30
P441L 53 75 6.4 5.6 7.4 3.5 8.9 2.0 9.4 77
P443S 1 100 6.6 6.6 6.6 6.6 6.6 6.6 6.6 100
F446I 79 47 5.4 4.0 6.5 2.3 8.6 1.6 10.0 32
G449A 6 67 6.6 4.5 7.1 2.3 9.5 2.3 9.5 67
N458Y 34 88 7.5 6.1 8.4 5.0 9.8 5.6 10.1 91
C469Y 1 100 6.2 6.2 6.2 6.2 6.2 6.2 6.2 100
M476I 8 63 6.1 4.2 7.1 3.5 7.9 3.5 7.9 71
K479I 4 75 6.4 5.8 6.8 5.4 7.0 5.4 7.0 100
A481V 5 40 4.9 4.7 6.0 2.7 7.6 2.7 7.6 40
S485N 2 50 4.7 3.7 5.8 3.7 5.8 3.7 5.8 50
L492S 1 0 4.3 4.3 4.3 4.3 4.3 4.3 4.3 0
Y493H 33 82 7.4 6.7 8.0 4.3 9.0 4.3 9.1 84
R515K 5 40 5.3 5.3 6.6 3.5 7.1 3.5 7.1 80
N525D 1 0 4.7 4.7 4.7 4.7 4.7 4.7 4.7 0
P527H/L* 21 29 4.8 4.2 5.6 3.4 6.0 3.3 6.3 67
G533A 4 50 5.6 5.2 6.3 5.0 6.9 5.0 6.9 100
N537I 8 13 5.1 4.5 5.4 3.9 6.3 3.9 6.3 63
G538 V 24 46 5.2 4.4 6.1 4.2 7.2 3.1 7.7 48
R539T 76 61 5.8 5.0 6.8 3.3 9.3 3.1 10.9 56
I543T 77 70 6.4 4.7 7.7 3.0 9.2 2.6 11.3 52
P553L 16 69 6.1 4.7 6.8 3.0 10.1 3.0 10.1 63
R561H 36 97 7.2 6.1 7.7 5.5 9.1 5.0 9.2 92
V568G 5 100 6.5 5.9 7.0 5.7 7.9 5.7 7.9 100
P574L 38 61 5.9 4.9 7.2 3.6 9.6 2.3 9.8 47
R575K 2 100 8.1 7.3 8.8 7.3 8.8 7.3 8.8 100
C580Y 450 74 6.6 5.5 7.6 4.1 9.3 2.3 13.9 75
D584V 1 0 5.4 5.4 5.4 5.4 5.4 5.4 5.4 100
F614L 2 0 3.3 2.5 4.1 2.5 4.1 2.5 4.1 50
P667T** 5 80 6.7 6.5 7.0 5.3 8.7 5.3 8.7 100
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between these two approaches, the proportion of pa-
tients with day 3 parasitemia in these data sets was com-
pared with the proportion of isolates with a PC1/2 > 5.5 h
(Table 5, Additional file 3: Figure S9). Use of the day 3
positivity test yielded an overall 11% (226/1975) false posi-
tive (FP) rate and 14% (107/772) false negative (FN) rate
when compared to the use of the cutoff of PC1/2 > 5.5 h.
However, since the initial parasitemia is a major deter-
minant of time to clear microscopy detectable parasites
after treatment, the proportion of FP and FN varies
across a range of initial parasitemia values with 51% FN
for parasite numbers less than 10,000/μL and 29% FP for
parasite numbers greater than 300,000/μL (Table 6).
Association of additional pfk13 mutant alleles with slow
parasite clearance
The current pooled analysis has allowed definition of add-
itional pfk13 genotypes that are associated strongly with
slow parasite clearance (Tables 3 and 7). Six pfk13 geno-
types have already been associated with slow clearance by
WHO, and 11 alleles were listed as candidates [57]. These
have all now been demonstrated to be strongly associated
with slow clearance (p < 0.001 except allele A481V, p =
0.002). In addition, 6 alleles that previously had been ob-
served infrequently were present in high enough numbers
in the analysis data set to allow assessment of the associ-
ated PC1/2; these alleles also showed a strong association
with prolonged parasite clearance. All of the associated
mutant alleles had single changes in the pfk13 propeller
region, with one exception, allele E252Q, located in the
N-terminal Plasmodium-specific region of the protein.
Two alleles with a smaller effect on parasite clearance,
E252Q and F446I, could now be assessed with confidence
since a larger sample size was available (n = 703 and n =
382, respectively). Parasites with the pfk13 E252Q muta-
tion had a median PC1/2 equal to 4.4 h and 11% had a
PC1/2 > 5.5 h, those that carried a F446I mutation had a
median PC1/2 of 5.4 h and a PC1/2 > 5.5 h was recorded in
47% of the patients.
Risk of bias
The risk of bias in individual studies was considered low
for majority of studies (Additional file 1).
Table 6 Utility of day 3 parasite positivity for detection of
isolates with long PC1/2 (> 5.5 h). False positive and false
negative outcomes are estimated over a range of initial
parasitemia values
Parasitemia (/μL) N False
positive %
False
negative %
< 10,000 127 0 51
10,000–50,000 491 3 26
50,000–100,000 804 5 8
100,000–300,000 887 14 3
≥ 300,000 438 29 0
All 2747 11 14
Table 5 Summary of PC1/2 by mutant codon and region showing proportion of isolates from a study site with PC1/2 > 5.5 h and
proportion of Day 3 positive isolates. Mutant codons represented by fewer than 5 isolates are indicated in bold (Continued)
N Patients with
PC1/2 > 5.5 h (%)
PC1/2 Percentiles (hours) Patients positive
on day 3 (%)Median 25 75 5 95 Min Max
A675V 49 76 6.7 5.5 7.3 3.4 8.4 1.4 8.8 80
A676D 1 0 3.4 3.4 3.4 3.4 3.4 3.4 3.4 0
H719N 2 50 5.6 5.5 5.8 5.5 5.8 5.5 5.8 50
Africa
WT 159 1 2.2 1.7 2.8 1.2 4.0 0.7 6.3 1
N87K 1 0 2.4 2.4 2.4 2.4 2.4 2.4 2.4 0
L143P 1 0 2.7 2.7 2.7 2.7 2.7 2.7 2.7 0
T149S 2 0 1.7 1.2 2.2 1.2 2.2 1.2 2.2 0
A175T 1 0 1.7 1.7 1.7 1.7 1.7 1.7 1.7 0
K189 T/N 33 3 2.1 1.7 2.5 0.9 4.6 0.8 7.1 0
R255K 3 0 2.0 0.8 2.2 0.8 2.2 0.8 2.2 0
S522C 1 0 2.4 2.4 2.4 2.4 2.4 2.4 2.4 0
A578S 2 0 1.8 1.1 2.6 1.1 2.6 1.1 2.6 0
Q613E 1 0 2.0 2.0 2.0 2.0 2.0 2.0 2.0 0
*20 P527H, one P527L, analyzed together; two P527H not analyzed since clearance data did not meet criteria
**5 P667T; one P667T not analyzed since clearance data did not meet criteria
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Sensitivity analysis performed after exclusion of the
only study (study ID 8, site ID 23) with moderate risk of
bias due to genotyping methods shows the same results
as analysis on the full dataset (Table 3). Only the mutant
codon I543T was reported at this study/site. Addition-
ally, one study site (study ID 13, site ID 15) presented
significantly different PC1/2 results from other sites for
parasites with no pfk13 mutant codons (Additional file 3:
Figure S1). The mutant codon P574L predominated in
that site. We tested the sensitivity of the association of
codon P574L with slow clearance by including and ex-
cluding the site ID 15 data (Table 3 and Table 7). The
association of the P574L codon with slow parasite clear-
ance was highly significant in both analyses (p ≤ 0.001).
Data from three apparently relevant published studies
were not shared [3, 22, 38]. However, the association of
particular mutations with slow clearing parasites coin-
cides with our analysis. In Southeast Asia, alleles Y493H,
539T, I543T, P553L, V568G, and C580Y in Thuy-Nhien
et al. [22] and C580Y, Y493H, and R539T in Ariey et al.
[3] were associated with slow clearance, and in Mali, the
9 pfk13 mutant parasites identified by Ouattara et al.
were not associated with slow clearance [38].
Discussion
This is the largest evaluation of the association of different
pfk13 mutations with slow parasite clearance following
antimalarial treatment with the artemisinin derivatives.
Table 7 List of new pfk13 mutant alleles strongly associated with slow parasite clearance
WHO designations This paper
Codon Status Codon N total isolates # sites N mutant % Prevalence: Median (Range)1 xPC1/2 (95% CI)
2
pfk13 mutant alleles associated with slow parasite clearance
N458Y Validated N458Y 1118 2 38 3 (2–4) 2.5 (2.2–2.9)
Y493H Validated Y493H 638 8 41 4 (2–19) 2.7 (2.3–3.1)
R539T Validated R539T 767 10 80 7 (2–53) 2.1 (1.9–2.4)
I543T Validated I543T 323 4 94 13 (4–81) 2.1 (1.8–2.4)
I543T* 240 3 27 10 (4–16) 2.8 (2.3–3.5)
R561H Validated R561H 1083 4 42 4 (3–6) 2.2 (1.9–2.6)
C580Y Validated C580Y 2343 14 536 21 (2–75) 2.3 (2.1–2.4)
pfk13 mutant alleles newly associated with slow clearance phenotype
E252Q Not assoc E252Q 1236 2 124 13 (10–16) 1.5 (1.4–1.6)
P441L Candidate P441L 1248 3 67 8 (5–10) 2.2 (2.0–2.4)
F446I Candidate F446I 764 7 98 31 (1–67) 1.5(1.4–1.7)
G449A Candidate G449A 88 3 7 15 (3–25) 1.9 (1.3–2.7)
M476I Low prev M476I 886 3 10 3 (1–3) 2.0 (1.5–2.5)
A481V Low prev A481V 852 3 10 8 (1–9) 1.6 (1.2–2.2)
R515K Low prev R515K 573 1 6 1 (1–1) 2.0 (1.5–2.7)
P527H Low prev P527H/L** 711 1 23 3 (3–3) 1.7 (1.5–2.0)
N537I/D Low prev N537I 656 2 10 3 (1–4) 1.8 (1.4–2.4)
G538V Candidate G538V 1163 2 27 2 (2–2) 1.9 (1.6–2.2)
P553L Candidate P553L 1112 4 18 6 (1–12) 2.2 (1.8–2.8)
V568G Candidate V568G 195 2 6 3 (2–4) 2.7 (1.8–4.1)
P574L Candidate P574L 1203 8 48 6 (2–50) 2.0 (1.7–2.2)
P574L*** 1177 7 35 5 (2–17) 1.8 (1.6–2.1)
P667T Low prev P667T 346 1 7 2 (2–2) 2.1 (1.6–2.9)****
A675V Candidate A675V 1114 1 53 5 (5–5) 2.2 (2.0–2.4)
1Prevalence is calculated per study site, combining data from all studies in that location, restricted to range of years when the mutation was observed
2Increase in PC1/2 compared to wild type; all p values for comparison with WT < 0.001. All have a half-life between 1.5 and 2.7 fold greater than the wild type.
WHO designations can be found in [57]
*With study ID 8, study site ID 23 (Tra Lang) removed
**20 P527H, one P527L, analyzed together, two P527H not analyzed since clearance data did not meet criteria
***With study ID 13, study site ID 15 (Pyin Oo Lwin) removed
****6 P667T, 1 P667R not analyzed since clearance data did not meet criteria
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Our study confirms that many, but not all (notably
A578S), mutations in the propeller region of the pfk13
gene are associated with slow parasite clearance. It also
shows that a mutation outside the propeller region,
E252Q which had been proposed to confer artemisinin
resistance, is strongly associated with slow parasite
clearance. This is also consistent with the increased
prevalence for several years on the northwest Thailand-
Myanmar border of parasites that carried the E252Q
mutation, presumably as a result of selection, before
the ascendance of the C580Y genotype conferring a more
extreme phenotype [18].
Several factors affect the rates of parasite clearance fol-
lowing administration of artemisinin derivatives and
would have contributed to the inter-individual and
between-site differences observed in this study. In infec-
tions with pfk13 wild type parasites, treatment with an
artemisinin derivative results in accelerated ring-form
clearance, and this is reflected in a steep slope of the
parasitemia-time profile and a derived PC1/2 which is
usually well below 5.5 h. Background immunity, or its
surrogate, age has a significant additional effect, further
accelerating parasite clearance. Thus, immunity as
reflected by antibody concentrations can have a rela-
tively small but significant effect [58]. Another import-
ant contributor to the half-life is the stage of parasite
development at the initial presentation of the patient.
This variable, too, could disproportionately affect clear-
ance of pfk13 mutant parasites compared to wild type
infections [59] but should only affect inter-individual
and not inter-site differences. In artemisinin combin-
ation treatments, the partner drug also makes a small
contribution to the rate of parasite clearance, which in
this study, was significant only for the mefloquine com-
bination, confirming previous findings [60]. It is import-
ant to note that despite modest site-specific differences,
the clearance half-life derived for each pf13 propeller al-
leles in the pooled data set was at least 1.5-fold higher
than the half-life of the wild type parasites, and for 14 of
the 20 propeller mutant alleles, the ratio of mutant to
wild type PC1/2 was between 2.0 and 2.7.
The prominent role of pfk13 propeller mutants in the
selective response to artemisinin drug pressure has been
recently demonstrated by the rapid increase in parasites
that carry a genotype with a particular version of the
C580Y allele. These parasites originated in northwestern
Cambodian and Thai foci and spread recently to new
areas of Cambodia and Vietnam [22, 32]. On a more
local scale, in this study, we found that the median PC1/2
of parasites that already carried a C580Y allele of pfk13
increased from 5.4 h in 2009 to 7.2 h in 2014 in the
western border region of Thailand. More widely, among
the 14 pfk13 propeller mutants newly associated with
slow clearance, 4 of the 14 mutant alleles associated with
slow clearance were present in at least 8% of the isolates
identified in the corresponding parasite population
(range 8–31%). Ten of the newly identified pfk13 mutant
alleles were present at low prevalence (range 1–6%) in
the sites where they have been reported and even among
the validated alleles, prevalence was below 10% for four
of the six alleles. Because the pooled data set contains
isolates collected from many different sites and over a
time span of 14 years, no trends in overall prevalence
can be inferred in this analysis. However, the value of
following temporal changes in the prevalence of propel-
ler mutants in local sites is clear, as has been demon-
strated for parasites that carry the C580Y allele in
Thailand, Cambodia, and Vietnam [22, 32].
Detailed temporal studies pfk13 mutant allele preva-
lence both in the GMS and in other worldwide sites rep-
resent a powerful tool for assessing whether a particular
pfk13 mutant population is increasing, a signal that fur-
ther studies of the parasite phenotype may be warranted
in that location. Temporal studies will be particularly
important for the seven newly identified propeller mu-
tant alleles in our data set that were observed at preva-
lences of 4% or lower.
In contrast, the pfk13 mutant parasites in all five Afri-
can sites remained at very low prevalence, generally
below 3%, and no evidence of slow-clearing parasites or
selection for mutant parasites has been identified. The
low prevalence of pfk13 mutant parasites in the African
studies in our data set depends on relatively small num-
bers of parasites (e.g., 31, 26, 29). However, the general-
ity of this observation is supported by extensive studies
in many sites in Africa including some assessments of
parasite clearance in vivo [37, 38, 61–63], protection
against parasite exposure to artemisinins of cultured par-
asites in vitro [10, 62, 64], and widespread molecular
surveillance of pfk13 propeller region sequence ([23–26,
55, 65–68] and see the WWARN K13 surveyor and
WHO drug resistance threats map for details). These
many reports also support the conclusions of our study:
in African sites, pfk13 propeller mutants are diverse but
rare, with no evidence for selection even where
artemisinin-based antimalarials have been intensively
used. Moreover, the pfk13 propeller mutant alleles com-
monly observed in Asia have rarely been observed in Af-
rica [40, 69]. In addition, only two African sites report a
somewhat higher prevalence of parasites with pfk13 pro-
peller mutations, 14% (18/130) in Mali [23] and an in-
crease from 3% (1/31) in 2007 to 27% (7/26) in 2014 in
Grande Comoros [70] and 17% (5/29) mutants in indi-
viduals from the neighboring island of Mayotte [71].
The pfk13 gene has been identified as essential to P. fal-
ciparum in its blood stream stage [72], and it is likely that
parasites dependent upon a mutant K13 protein would
incur a considerable fitness disadvantage [64]. In this
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situation, parasite populations subjected to intensive use
of artemisinin-based antimalarials would be expected to
be under intense selection for pfk13 mutant parasites that
carry additional genetic changes that could compensate
for the fitness cost as has been observed in other parasite
populations under drug selection [73]. There is increasing
evidence that such adaptive responses have evolved in
Southeast Asian P. falciparum populations [74]. For ex-
ample, intensive use of the ACT dihydroartemisinin-
piperaquine in Cambodia and Thailand has apparently
exerted further selection on the parasites that carry the
pfk13 C580Y “spreading” genotype, selecting parasites that
also carry an increased copy number of plasmepsin 2–3
that confers resistance to the piperaquine partner drug
[33–35]. In addition to selection and spread of pfk13 mu-
tant parasites, independent populations that carry new
versions of the common C580Y or one of many novel
pfk13 alleles have emerged in many other sites within the
GMS region [12–15, 21, 22, 28, 54].
Even before the pfk13 gene was identified as a po-
tential molecular marker of reduced artemisinin re-
sponse, genome-wide association studies identified
several regions of the P. falciparum genome associ-
ated with slow parasite clearance on chromosomes 10
and 14, in addition to chromosome 13 where the
pfk13 gene is located [5, 6, 75]. Whole genome ana-
lyses have also identified genetic changes associated
both with pfk13 propeller mutants and with slow
clearance in independent, low diversity populations in
Cambodia [76, 77] and in Western Thailand [78]. Par-
asites that carry these additional genetic changes are
present in many populations in the western regions of
Southeast Asia [21, 28, 79]. Moreover, the importance
of other genetic changes for the expression of the
slow clearance phenotype has been observed in vitro.
Introduction of a pfk13 mutant allele into a cloned,
fast-clearing wild type parasite of recent Cambodian origin
conferred more protection against dihydroartemisinin in
vitro than when the same allele was expressed in a wild
type parasite line of African origin [10]. These observations
support the interpretation that the independent emergence
of parasite populations with new pfk13 alleles is facilitated
in Southeast Asia by the presence of local parasite popula-
tions with genomes already adapted to support pk13 mu-
tant parasites when they arise. Exposure to artemisinins
could then quite rapidly select emergence and selection of
a local population of pfk13 mutant parasites.
These specific adaptive genomic changes that are com-
mon in Southeast Asian parasites have not been observed
in African isolates, but comprehensive analyses have not
yet been undertaken [28]. The slow clearance phenotype
is extremely complex, dependent on changes in the overall
stress response to artemisinins (see [80, 81] for compre-
hensive reviews) and there may be many other
combinations of adaptive genomic changes that could
support the fitness of pfk13 mutant parasites. In addition,
it is clear that genetic changes other than pfk13 mutations
can confer diminished response to artemisinins in vitro
and in vivo [82–85] and surveillance plans will need to re-
main open to the possibility of these alternative genetic
strategies.
This meta-analysis still depends on detailed multiple
quantitative assessments of the parasite count, not an
approach that is likely to be feasible for routine surveil-
lance in many study sites. This study highlights the limi-
tations in sensitivity and specificity of the standard
assessment of parasite clearance on day 3 as a pheno-
typic signal of delayed clearance. There is no question
that simpler methods for assessment of parasite re-
sponses to artemisinins will be needed in all endemic
areas, with particular attention to areas where malaria
transmission is low and drug pressure will be most likely
to select resistance.
Our large data set allowed identification of signifi-
cant association of pfk13 parasite genotype and PC1/2
phenotype even when the sample size of parasites
with a particular allele was very small. For example,
four different mutant alleles were observed in fewer
than eight patient isolates. Even in these cases, the
analysis allowed a strong genotype-phenotype associ-
ation to be identified. Among these rare mutant al-
leles, the ratio of mutant to wild type PC1/2 ranged
from 1.9 to 2.7, ten of the mutant alleles are present
in more than 10% of the parasites in the tested iso-
lates, and all but four were observed in more than
one study site. This robust outcome demonstrates
that analyses of the PC1/2 in patients can allow identi-
fication of mutant pfk13 alleles associated with
slow-clearing parasites even when malaria transmis-
sion is low and few patients can be assessed. This
suggests that some researchers in areas outside the
GMS may be able to assess the PC1/2 phenotype in
vivo [11, 37, 38, 61] or parasite responses to artemisi-
nins in vitro [10, 62, 85–87] as a screen for artemisi-
nin response as some groups have already done.
Finally, 18 data sets were included in this
meta-analysis of individual patient data sets, including
4 trials that had not yet been published. We believe
that this demonstrates that the engagement of re-
search groups to share individual patient data can pro-
vide a unique opportunity for advancement of public
health. This approach can combine and facilitate col-
laborative analysis of critical data sets, defining out-
comes that cannot be achieved by only extracting
outcomes from multiple single publications. Such
meta-analyses can provide evidence for policy makers,
while not precluding subsequent individual study
publications.
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There are limitations of this meta-analysis. Notably,
the uneven representation of isolates derived from dif-
ferent sites of origin between Africa and Asia and
within Southeast Asia and the imbalance of longitu-
dinal data among the sites. The extensive long-term
record of clinical outcomes of artemisinin treatment
from patients on the Thai Western Border contributed
many more isolates to the available data set than any
other site (1291/3087, 42%). However, this rich sample
set is itself diverse, contributing information on 31 of
the 44 mutant alleles observed in the Asian data set.
Moreover, the patients studied were not from a very
limited area, but came from sites situated over an ex-
tended region of the northwest Thai/eastern Myanmar
border. The diversity of propeller mutant genotypes
supports the assumption that this large number of iso-
lates from the Thai Western Border is representative of
the Eastern part of the whole region that includes
Thailand, Cambodia, Lao PDR, and Vietnam.
Conclusions
The slow clearance phenotype that has evolved in P.
falciparum parasite populations in response to artemi-
sinin challenge is complex and can involve at least
one non-synonymous change in the P. falciparum--
specific region of the pfk13 gene, but most frequently,
specific single mutations in the propeller region.
These different propeller mutations may also com-
promise parasite fitness, so genomic studies that fur-
ther define the other genomic changes in parasite
populations that support pfk13 mutants to overcome
fitness deficits will be needed.
Despite this complexity of the phenotype, the ap-
pearance and selection of mutations in the pfk13 pro-
peller region are valuable markers for surveillance of
diminished artemisinin responsiveness in parasite
populations. This meta-analysis demonstrates that 14
pfk13 propeller mutants, in addition to the 6 previ-
ously validated, are associated with prolonged parasite
clearance and could be considered for implementation
as molecular markers in the Greater Mekong Sub-
region, as a potential early signal of slow parasite
clearance.
The confirmation of the apparent absence outside
of Southeast Asia of common pfk13 alleles associated
with slow clearance is welcome. However, testing of a
more practical and sensitive protocol than persistence
of parasites on day 3 that can be a first signal of pro-
longed parasite clearance is urgently needed. Such an
approach should also include vigilance for diminished
artemisinin responses signaled by increasing preva-
lence of parasites with mutant alleles of pfk13 or of
other genetic changes that may also diminish parasite
responses to artemisinins.
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